Longevity biotech clock.bio has launched with $4 million in funding to develop regenerative medicines to prevent and treat age-related diseases. The company says its immediate objective is to decode all rejuvenation programmes present in human cells, to build an atlas of disease and rejuvenation targets for clinical translation. “We have a bold mission of extending […]
